$VSTM In a preclinical pharmacology setting, duvelisib was shown to be highly potent, with investigators noting a whole blood IC50 of 0.36 nM for delta subunit inhibition and whole blood IC50 of 19.6nM for gamma subunit inhibition. The agent was shown to double T cells in both patients with CLL, as well as healthy volunteers from 40 nM to 0.4 mM over 9 to 14 days.
  • 6